Merck Serono

Typ: Företag

Namn: Merck Serono

Läs mer på våra internationella sajter:

silobreaker

272 dokument

Publicerad 06 Feb 2012 - uppdaterad 07 Feb 2012 - 1 Dokument

Merck KGaA

Rebif® godkänt för behandling efter första skovet vid Multipel Skleros

Receives European Approval to Expand Use of Rebif® in Patients with Early Multiple Sclerosis. Geneva, Switzerland, January 25, 2012 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) has approved ... [ Publicerad 06 Feb 2012 av MyNewsDesk ]

Entiteter: Rebif, Merck Serono, REFLEX, Merck KGaA

Publicerad 09 Jan 2012 - uppdaterad 10 Jan 2012 - 2 Dokument

Ablynx

ABLYNX TO PRESENT PROGRESS IN 2011 AND ITS 2012 STRATEGY AT 30TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

- Ablynx [Euronext Brussels: ABLX] today announced that it will present a review of its progress in 2011, together with an outline of the Company's evolving strategy and a review of its portfolio and priorities for 2012, at the 30th Annual J.P. Morgan ... [ Publicerad 09 Jan 2012 av BolagsFakta.se ]

Entiteter: Ablynx, JPMorgan Chase & Co, Progress, Edwin Moses

Publicerad 10 Jan 2012 - uppdaterad 10 Jan 2012 - 1 Dokument

Start up-bolag får kapital från Big Pharma

Två dagar in på det nya året bildades ett nytt bioteknikbolag, Galecto Biotech. Redan vid starten har bolaget två starka investerare i ryggen. - Vi har fått totalt fem miljoner euro i tre omgångar. Investeringarna kommer från Novos investeringsfond Novo ... [ Publicerad 10 Jan 2012 av IDG.se ]

Entiteter: Big Pharma, Merck Serono, Ulf Nilsson (The Liberal Party (SWE)), Lund

Publicerad 12 Dec 2011 - uppdaterad 12 Dec 2011 - 1 Dokument

Edwin Moses

ABLYNX AND MERCK SERONO SELECT A NOVEL NANOBODY CANDIDATE, ALX-0761, FOR PRE-CLINICAL DEVELOPMENT

- Ablynx [Euronext Brussels: ABLX] and partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that they have advanced the Nanobody candidate, ALX-0761, into pre-clinical development for the treatment of autoimmune diseases. ... [ Publicerad 12 Dec 2011 av BolagsFakta ]

Entiteter: Ablynx, Merck Serono, Edwin Moses, Merck KGaA, Darmstadt (Germany)

Citat

...Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "We are excited that Boehringer Ingelheim has already submitted a CTA for this Nanobody. This development candidate has the potential to be a first-in-class therapy for Alzheimer's disease and demonstrates the power of our Nanobody platform. We look forward to seeing this programme enter the clinic over the coming months." About Alzheimer'sAlzheimer's disease Alzheimer's disease is the most common form of dementia in adults. It is estimated to affect 4...

NANOBODY FOR ALZHEIMER"S DISEASE FROM THE ALLIANCE WITH BOEHRINGER INGELHEIM MOVES CLOSER TOWARDS ... [BolagsFakta - 25 Apr 2012]

ABLYNX "S PARTNER SHOWS THAT A NANOBODY CAN ELICIT SUPERIOR ANTI-TUMOUR EFFICACY COMPARED TO CONVENTIONAL MONOCLONAL ANTIBODY APPROACHES"

ABLYNX"S PARTNER SHOWS THAT A NANOBODY CAN ELICIT SUPERIOR ANTI-TUMOUR EFFICACY COMPARED TO CONVE ... [BolagsFakta - 04 Apr 2012]

...Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "We are excited that Novartis has obtained IND approval and that they will bring this first Nanobody into clinical development in an oncology setting. This development candidate demonstrates the power of the Nanobody platform in addressing complex target classes that are challenging to address with conventional antibodies." About Investigational New Drug Application (IND) An IND is an application that a drug sponsor must submit to U S FoodFood and Drug Administration (FDA)...

ABLYNX RECEIVES MILESTONE PAYMENT AS COLLABORATOR RECEIVES IND APPROVAL FOR A NANOBODY IN ONCOLOGY [BolagsFakta - 02 Apr 2012]

Mer innehåll

Sortera på: datum \| relevans
ABLYNX ANNOUNCES Q1 2012 BUSINESS UPDATE [ Publicerad 16 May 2012 av BolagsFakta ]
ABLYNX ANNOUNCES Q1 2012 BUSINESS UPDATE [ Publicerad 16 May 2012 av BolagsFakta.se ]
NANOBODY FOR ALZHEIMER"S DISEASE FROM THE ALLIA... [ Publicerad 25 Apr 2012 av BolagsFakta ]
ABLYNX"S PARTNER SHOWS THAT A NANOBODY CAN ELIC... [ Publicerad 04 Apr 2012 av BolagsFakta ]
ABLYNX RECEIVES MILESTONE PAYMENT AS COLLABORAT... [ Publicerad 02 Apr 2012 av BolagsFakta ]
ABLYNX ANNOUNCES AN EXTENSION OF ITS GLOBAL STR... [ Publicerad 20 Mar 2012 av BolagsFakta ]
Record high numbers of presenting companies at ... [ Publicerad 16 Mar 2012 av BolagsFakta ]
Biotie"s Stock Exchange Releases published in 2011 [ Publicerad 08 Mar 2012 av BolagsFakta ]
Biotie's Stock Exchange Releases published in 2... [ Publicerad 08 Mar 2012 av BolagsFakta.se ]
ABLYNX ANNOUNCES 2011 FULL YEAR RESULTS (Ablynx) [ Publicerad 22 Feb 2012 av BolagsFakta.se ]
ABLYNX ANNOUNCES 2011 FULL YEAR RESULTS [ Publicerad 22 Feb 2012 av BolagsFakta ]
Mendor Announces Partnership with Merck Serono ... [ Publicerad 14 Feb 2012 av BolagsFakta ]
Rebif® godkänt för behandling efter första skov... [ Publicerad 06 Feb 2012 av MyNewsDesk ]
ABLYNX RECEIVES ANOTHER MILESTONE AS BOEHRINGER... [ Publicerad 01 Feb 2012 av BolagsFakta.se ]
ABLYNX STATEMENT ON PRESS ARTICLE AND RELATED S... [ Publicerad 23 Jan 2012 av BolagsFakta ]
ABLYNX IS GRANTED EXTENDED GMP CERTIFICATE FOR ... [ Publicerad 10 Jan 2012 av BolagsFakta.se ]
Start up-bolag får kapital från Big Pharma [ Publicerad 10 Jan 2012 av IDG.se ]
ABLYNX TO PRESENT PROGRESS IN 2011 AND ITS 2012... [ Publicerad 09 Jan 2012 av BolagsFakta.se ]
ABLYNX TO PRESENT PROGRESS IN 2011 AND ITS 2012... [ Publicerad 09 Jan 2012 av BolagsFakta ]
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT... [ Publicerad 04 Jan 2012 av BolagsFakta.se ]
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT... [ Publicerad 04 Jan 2012 av BolagsFakta ]
ABLYNX AND MERCK SERONO SELECT A NOVEL NANOBODY... [ Publicerad 12 Dec 2011 av BolagsFakta ]
ABLYNX AND MERCK SERONO EXPAND THEIR PARTNERSHI... [ Publicerad 09 Nov 2011 av BolagsFakta ]
Biotie Therapies Corp. Interim report 1 January... [ Publicerad 04 Nov 2011 av BolagsFakta ]
Merck Serono introducerar RebiDose™- Den första... [ Publicerad 07 Jun 2011 av Webfinanser ]
Erbitux förbättrar överlevnaden med 5.1 månader... [ Publicerad 07 Jun 2011 av Medicinsk Access ]
Erbitux förbättrar överlevnaden med 5.1 månader... [ Publicerad 04 Jun 2011 av Webfinanser ]
Erbitux förbättrar överlevnaden med 5.1 månader... [ Publicerad 04 Jun 2011 av Merck Serono ]
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT... [ Publicerad 31 May 2011 av Cision Wire ]